Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

India Globalization Capital Provides Update on Hyalolex for Alzheimer’s Commercialization Strategy

Posted on: 14 Dec 17

BETHESDA, Md., Dec. 14, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC) today provides an update on corporate initiatives to launch its lead product for Alzheimer’s, Hyalolex, through licensed medical dispensaries in the U.S.  Investors and interested parties are encouraged to visit for information on Alzheimer’s disease and research data related to our product formulation.

Hyalolex Liquid Formulation

As previously reported, IGC has a two-part strategy for commercializing its lead product, Hyalolex.  It is anticipated, subject to adequate funding, to move the Alzheimer’s formulation through FDA registered pre-clinical and clinical trials.  Independent of the FDA process, IGC expects to license its formulation technology for distribution as a Complimentary and Alternative Medicine (CAM) through licensed medical cannabis dispensaries in key markets of the U.S.  This process will include state-by-state sourcing, formula assembly, packaging and distribution utilizing best practices to ensure quality control while complying with the current legal guidelines established by each individual state in which Hyalolex is sold.  Medical cannabis is currently legal in 29 states and in Washington, D.C.

Early 2018 Initial Rollout / Marketing Program

IGC has identified dispensaries in Washington, D.C. and Maryland as initial distribution sites to launch the product once final inventory is secured.  This is expected to occur in early 2018 with subsequent expansion into additional U.S. states dependent on product procurement and associated compliance achievement.  In anticipation of this, IGC has retained The Medical Marketing Group, Inc., a provider of outsourced product-detailing, education and outreach services to assist with the Company’s national dispensary expansion ambitions.

Alzheimer’s patients suffer from a host of symptoms including anxiety, agitation, and sleep disorders. The hallmarks of Alzheimer’s include plaques, tangles, and dementia. Hyalolex has been shown to decrease plaques and tangles, control anxiety, and help with sleep disorders thorough a patent-pending pathway.  Based on these and other studies, we expect to bring Hyalolex to market in early 2018, with the hope of bringing much needed relief to Alzheimer’s patients.

About IGC

The Company has two lines of businesses: a legacy infrastructure business and a cannabis pharmaceutical business that has developed a lead product for treating Alzheimer’s patients.  It is also engaged in the development of cannabis based combination therapies to treat pain, nausea, eating disorders, several endpoints of Parkinson’s, and epilepsy in dogs and cats.  The company is based in Maryland, USA.

For more information please visit
Follow us on Twitter @IGCIR and

Forward-looking Statements

Please see forward-looking statements and risk factors as discussed in detail in IGC's Form 10K for fiscal year ended March 31, 2017, and in other reports filed with the U.S. Securities and Exchange Commission.

Claudia Grimaldi



Last updated on: 15/12/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.